Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 12/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632453 | 1.00 | FBP1 (1.00) | FBP1PRMT1ALDH1A1TSHRAKR1C3 | |
| SCHEMBL632451 | 1.00 | FBP1 (1.00) | FBP1PRMT1ALDH1A1TSHRAKR1C3 | |
| SCHEMBL28488527 | 0.80 | FBP1 (0.70) | FBP1ALDH1A1 | |
| SCHEMBL28485590 | 0.80 | FBP1 (0.70) | FBP1ALDH1A1 | |
| SCHEMBL13983962 | 0.80 | FBP1 (0.70) | FBP1ALDH1A1 | |
| SCHEMBL630964 | 0.80 | FBP1 (1.00) | FBP1ALDH1A1AKR1C3 | |
| SCHEMBL630963 | 0.80 | FBP1 (1.00) | FBP1ALDH1A1AKR1C3 | |
| SCHEMBL525207 | 0.80 | FBP1 (1.00) | FBP1ALDH1A1AKR1C3 | |
| SCHEMBL30295762 | 0.80 | FBP1 (1.00) | FBP1ALDH1A1AKR1C3 | |
| SCHEMBL6912556 | 0.79 | FBP1 (0.65) | FBP1PRMT1AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419094-B1 | Compounds for the treatment of mitochondrial diseases | CENTRE NAT RECH SCIENT (FR) | 2016-06-08 | — | — | EP | disclosed |
| US-9315482-B2 | Derivatives useful as antiviral agents | INSTITUT PASTEUR (FR) | 2016-04-19 | — | — | US | disclosed |
| US-20130210886-A1 | Novel Derivatives Useful as Antiviral Agents | INSTITUT PASTEUR (FR) | 2013-08-15 | — | — | US | disclosed |
| US-20120329834-A1 | COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-12-27 | — | — | US | disclosed |
| EP-2420495-A1 | Novel derivatives useful as antiviral agents | Institut Pasteur (FR) | 2012-02-22 | — | — | EP | disclosed |
| EP-2243476-A1 | Compounds for the treatment of mitochondrial diseases | Centre National de la Recherche Scientifique (FR) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210886-A1 | Novel Derivatives Useful as Antiviral Agents | MAVS, IRF3, IFNAR1 | FBP1 1867/4885PRMT1 219/4885ALDH1A1 1663/4885 |
| US-20120329834-A1 | COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | PC, CS, COQ8A | FBP1 494/4885PRMT1 1474/4885ALDH1A1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.